ClinicalTrials.gg
Active, not recruitingNCT06669455SENSSUpdated Apr 1, 2026

An Integrated and Personalized Lifestyle Approach for People With Parkinson's Disease

An interventional study of Personalized and combined lifestyle approach in Parkinson Disease, sponsored by Radboud University Medical Center. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.

Planned enrollment
7th of 22
256 · median 188
Started
2024
with 2 others
No phase
15 of 34
3 open now
Primary completion
2027-03
later than 7 of 11 live
Registered
32nd of 34
by date

Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 32nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease by Radboud University Medical Center, or all of them as a file.
02

Study summary

The goal of this study is to investigate the effects of a combined lifestyle program on the quality of life in people with Parkinson's Disease.

Participants will be randomly assigned to one of two groups, both receiving standard care, a Parkinson Lifestyle Decision aid and an intake meeting with a lifestyle coach. One group will work on their goals independently, while the other group will get guidance from the lifestyle coach throughout the 12-month program. The program focuses on self-management, exercise, nutrition, sleep and stress.

Participants will complete questionnaires after 0, 6 and 12 months, and use a wearable sensor for two weeks. The main outcome is quality of life over 12 months, measured with the PDQ-39 questionnaire. The study also examines personal goal achievements, symptom changes, and the economic effects of the program.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Lifestyle
  • Personalized
  • Stepped Care
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson's disease (idiopathic) in all stages of severity
  • Proficient in Dutch, for both the data collection (questionnaires) and the intervention (all of the apps/modules are in Dutch)
  • Aged 18 or older

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairments that do not allow to fill out the questionnaires, as judged by the researcher during the screening call.
  • Not in possession of or no access to an electronic device that allows for (video) calls with a lifestyle coach, and to complete questionnaires.
  • Planned surgery or a planned major change in healthcare provision.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intervention group receiving: * Intake with lifestyle coach * Usual Care * Integrated, combined lifestyle approach (SENSS), including continuous monitoring by lifestyle coach.

    Behavioral: Personalized and combined lifestyle approach

  • No intervention
    Control

    Control group receiving: * Intake with lifestyle coach * Usual care

Interventions

  • BehavioralPersonalized and combined lifestyle approach

    In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.

06

What researchers measure

Primary outcomes

  1. Change in quality of life measured with the PDQ-39.

    The PDQ-39 consists of 39 questions across 8 dimensions of daily living including relationships, social situations and communication. Item scores range on a 5-point scale from "never" to "always". Both the total score of the PDQ-39 and the scores for each of the 8 dimensions are considered primary outcomes.

    Time frame: Measured at baseline, and after 6 and 12 months.

Secondary outcomes

  1. Health related quality of life

    EuroQol 5D-5L (EQ-5D-5L); The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'.

    Time frame: Measured at baseline, and after 6 and 12 months.

  2. Parkinson's Disease Symptoms

    The Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) part 1b and part 2. Questions are answered using a 0-4 likert scale ranging from 0 normal to 4 severe.

    Time frame: Measured at baseline, and after 6 and 12 months.

  3. Fatigue

    Fatigue Severity Scale (FSS); This questionnaire consists of nine questions, each rated on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree). A higher score indicates greater fatigue or a more significant impact of fatigue on daily life.

    Time frame: Measured at baseline, and after 6 and 12 months.

  4. Goal Attainment

    The visual analogue scale (VAS) is used to evaluate the lifestyle goals that participants set at the start of the intervention. The VAS is a non-specific measurement tool where patients rate their experience of a given sensation on a scale from 0 to 10.

    Time frame: Measured at baseline, and after 6 and 12 months.

  5. Diet quality

    The Dutch Healthy Diet index 2015 (DHD15-index) consists of fifteen components representing the fifteen food-based Dutch dietary guidelines of 2015. Per component the score ranges between 0 and 10, resulting in a total score between 0 (no adherence) and 150 (complete adherence).

    Time frame: Measured at baseline, and after 6 and 12 months.

  6. Mood (Anxiety and Depression)

    The Hospital Anxiety and Depression Scale (HADS) measures symptoms of anxiety and depression using a 14-item self-report questionnaire, over the past four weeks. It consists of a 7-item anxiety subscale and a 7-item depression subscale. Higher scores on the HADS indicate more symptoms, with a total score range of 0-42.

    Time frame: Measured at baseline, and after 6 and 12 months.

  7. Physical activity level

    The LASA Physical Activity Questionnaire (LAPAQ) consists of 37 items designed to measure physical activities performed over the past week. The questionnaire assesses the frequency and duration of various physical activities. A higher score on the LAPAQ indicates a greater amount of time spent on physical activities.

    Time frame: Measured at baseline, and after 6 and 12 months.

  8. Insomnia

    The Insomnia Severity Index (ISI) consists of seven items that assess various aspects of insomnia. The questionnaire includes the insomnia severity, satisfaction with sleep and impact on daily functioning. Each item is rated on a five-point Likert scale from 0 (not at all) to 4 (extremely), based on the last two weeks. The total score ranges from 0 to 28, with higher scores indicating greater insomnia severity.

    Time frame: Measured at baseline, and after 6 and 12 months.

  9. Sleepiness

    The Epsworth Sleepiness Scale (ESS) is a questionnaire that measures daytime sleepiness by assessing the likelihood of dozing or sleeping in eight different situations on a scale from 0 (would never doze or sleep) to 3 (high chance of dozing or sleeping). The total score ranges from 0 to 24, with higher scores indicating greater sleepiness.

    Time frame: Measured at baseline, and after 6 and 12 months.

  10. Self-Efficacy

    The General Self-Efficacy Scale (GSES) is a 10-item questionnaire (total score range of 10-40) designed to measure a general sense of perceived self-efficacy. A higher score represents higher self-efficacy.

    Time frame: Measured at baseline, and after 6 and 12 months.

  11. Ilness Acceptance

    Acceptance of Disease and Impairments Questionnaire (ADIQ); The questionnaire contains 14 items with a 4-point Likert scale ranging from 1 (disagree) to 4 (entirely agree).

    Time frame: Measured at baseline, and after 6 and 12 months.

  12. Coping

    The ways of coping questionnaire (WCQ); Measures coping on eight dimensions. The questionnaire consists of 67 statements regarding coping in stressful situations. Participants have to score how much they think each statement applies to their situation on a 4-points Likert scale ranging from 0 ("does not apply and/or not used") to 3 ("used a great deal").

    Time frame: At baseline.

  13. Self-management

    The Patient Activation Measure (PAM) is a 13-item survey that assesses an individual's self-reported knowledge, skills, and confidence in managing their health or chronic condition. Each item is rated on a 4-point Likert scale from "totally disagree" to "totally agree" or "non-applicable.

    Time frame: Measured at baseline, and after 6 and 12 months.

  14. Change in physical activity from baseline to 12 months

    Movement data captured with accelerometry data from a wrist worn wearable sensor (Empatica EmbracePlus).

    Time frame: Measured one week at baseline and one week after 12 months.

  15. Change in sleep time from baseline to 12 months

    Captured with accelerometry and photoplethysmogry data from a wrist worn wearable sensor (Empatica EmbracePlus).

    Time frame: Measured one week at baseline and one week after 12 months.

  16. Change in sleep quality from baseline to 12 months

    Captured with accelerometry and photoplethysmogry data from a wrist worn wearable sensor (Empatica EmbracePlus).

    Time frame: Measured one week at baseline and one week after 12 months.

Other outcomes

  1. Healthcare costs

    Data on the used healthcare services used in the past 6 months will be collected with a questionnaire. The calculation uses tarrifs as determined for services for the healthcare in the Netherlands.

    Time frame: At 6 and 12 months.

  2. Intervention costs

    The costs of the intervention consists of the amount of guidance provided by the lifestyle coach and the facilities used within the intervention, such as usage of a digital tool or online training. In the monitoring sessions with the lifestyle coach participants are asked what facilities they used in the prior period. This is registered by the lifestyle coach for each participant.

    Time frame: During the intervention (from baseline until 12 months).

  3. Process Evaluation

    In a process evaluation, caried out alongside the RCT, we aim to explore the experiences of participants and the lifestyle coaches with the SENSS approach. This process evaluation will take place through interviews with a selection of the participants and the lifestyle coaches.

    Time frame: After completion of the 12 months intervention.

  4. Caregiver strain

    If the participants have a caregiver that is willing to participate in the study they receive a questionnaire and some follow-up questions about their task as caregiver and working life. Care Giver Strain Index (CSI); consists of 13 yes/no questions about the perceived strain. A higher score represents more strain. The caregivers will receive some questions about the amount of care they give and if/how this affects their working life. The results of these questions will be used in the analysis on (socio)economic impact.

    Time frame: Measured at baseline, and after 6 and 12 months.

07

Study locations

1 site
08

References and documents

Publications

  • Gaveel TJ, Postma EM, Bloem BR, Darweesh SKL, Munneke M, Overbeek K, Helmich R, Zeevat F, Zijlstra M, Boersma C, Overeem S, Pijpers A, Jakimowicz C, van Gilst MM, Speckens AEM, The R, Manhoudt G, van der Wel A, Duits AA, de Vries NM. The SENSS (Stress, Exercise, Nutrition, Sleep, Self-management) study: study protocol for a randomized controlled trial to evaluate an integrated, personalized and stepped care lifestyle approach for people with Parkinson's disease. Front Neurol. 2026 Mar 3;17:1752073. doi: 10.3389/fneur.2026.1752073. eCollection 2026. PubMed 41853177 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 28 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 1, 2024
StartActual
Nov 12, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669455
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Nov 12, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion